Skip to main content
Erschienen in: Drug Safety 6/2003

01.05.2003 | Review Article

A Benefit-Risk Assessment of Ofloxacin Otic Solution in Ear Infection

verfasst von: Talen K.H. Wai, Dr Michael C.F. Tong

Erschienen in: Drug Safety | Ausgabe 6/2003

Einloggen, um Zugang zu erhalten

Abstract

Ofloxacin is a fluoroquinolone antibacterial with potent bactericidal activities and the topical otological preparation of this drug has been clinically utilised since the late 1980s. The rate of eradication with ofloxacin ranges from 83.3% to 100% for all pathogens commonly isolated from middle ear effusions in cases of otitis media and otitis externa. Despite the significant length of its usage, emergence of resistant pathogens has been rarely encountered in clinical trials; only two strains of Pseudomonas aeruginosa have been documented with decreased susceptibility to ofloxacin following the use of the otic solution.
Ear infections, including otitis externa, chronic suppurative otitis media and otorrhoea associated with tympanostomy tubes, are common problems in clinical practice. The potential complications associated with ear infection can be otological, extratemporal, or even psychosocial. They are sometimes fatal and the effect can be long-lasting and detrimental. The use of an effective topical antibacterial with high cost-effectiveness is definitely warranted. As regards various clinical aspects, including overall success rate, symptomatic relief of otalgia and otorrhoea, ofloxacin otic solution was found to be more effective than comparator agents, be it a topical antibacterial, a systemic antibacterial or combination drugs.
The systemic absorption of fluoroquinolones is minimal after topical application. Ofloxacin otic solution 0.3% has been shown to have a low rate of adverse drug reactions. Adverse reactions to ofloxacin otic solution were generally mild. The lack of ototoxic effect from ofloxacin eardrops, even in the concentration higher than 0.3%, has been demonstrated in animal studies. In the clinical setting, no increase in bone-conduction threshold has been shown after the treatment of topical ofloxacin otic solution. There have not been any reports of ototoxicity with ofloxacin otic solution since its approval.
To conclude, ofloxacin otic solution 0.3% is clinically effective in the treatment of otitis externa and chronic suppurative otitis media in particular with respect to the overall cure rate, relief of otalgia and otorrhoea. It is well tolerated, with minimal adverse effects. It is not associated with any ototoxicity both experimentally and clinically.
Literatur
1.
Zurück zum Zitat Goldblatt E, Dohar J, Nozza R, et al. Topical versus systemic amoxicillin/clavulanate in purulent otorrhea in children with tympanostomy tubes. Inter J Pediatr Otorhinolaryngol 1998; 46: 91–101CrossRef Goldblatt E, Dohar J, Nozza R, et al. Topical versus systemic amoxicillin/clavulanate in purulent otorrhea in children with tympanostomy tubes. Inter J Pediatr Otorhinolaryngol 1998; 46: 91–101CrossRef
2.
Zurück zum Zitat Ohyama M, Furuta S, Kazyuyoshi U, et al. Ofloxacin otic solution in patient with oitis media. Arch Otolaryngol Head Neck Surg 1999; 125: 337–40PubMed Ohyama M, Furuta S, Kazyuyoshi U, et al. Ofloxacin otic solution in patient with oitis media. Arch Otolaryngol Head Neck Surg 1999; 125: 337–40PubMed
3.
Zurück zum Zitat Daiichi Pharmaceutical Corporation, 2002. (Data on file.) Daiichi Pharmaceutical Corporation, 2002. (Data on file.)
4.
Zurück zum Zitat Daiichi Pharmaceutical Corporation, 2002. (Data on file.) Daiichi Pharmaceutical Corporation, 2002. (Data on file.)
5.
Zurück zum Zitat Floxin Otic (ofloxacin otic solution) 0.3%. Package insert. Daiichi Pharmaceutical Corporation drug prescribing information Floxin Otic (ofloxacin otic solution) 0.3%. Package insert. Daiichi Pharmaceutical Corporation drug prescribing information
6.
Zurück zum Zitat Hooper DC. Quinolone mode of action-new aspects. Drugs 1994; 45Suppl. 3: 8–14 Hooper DC. Quinolone mode of action-new aspects. Drugs 1994; 45Suppl. 3: 8–14
7.
Zurück zum Zitat Simpson KL, Markham A. Ofloxacin otic solution: a review of its use in the management of ear infections. Drugs 1999; 58(3): 509–31PubMedCrossRef Simpson KL, Markham A. Ofloxacin otic solution: a review of its use in the management of ear infections. Drugs 1999; 58(3): 509–31PubMedCrossRef
8.
Zurück zum Zitat Agro A, Garner ET. Single dose, double-blind, placebo-controlled parallel group study to assess the pharmacokinetics and penetration of ofloxacin otic solution through a tympanostomy tube in adults without active otitis media. Daiichi Pharmaceutical Corporation, 1995, 1996 Study report protocol 82DA-PRT 004. (Data on file) Agro A, Garner ET. Single dose, double-blind, placebo-controlled parallel group study to assess the pharmacokinetics and penetration of ofloxacin otic solution through a tympanostomy tube in adults without active otitis media. Daiichi Pharmaceutical Corporation, 1995, 1996 Study report protocol 82DA-PRT 004. (Data on file)
9.
Zurück zum Zitat Agro A, Garner ET., McLean PH. Single dose, double-blind, placebo-controlled parallel group study to assess the pharmacokinetics and penetration of ofloxacin otic solution through a tympanostomy tube in adults with suppurative otitis media with otorrhoea. Daiichi Pharmaceutical Corporation, 1995, 1996 Study report protocol 8280-A-PRT 005. (Data on file) Agro A, Garner ET., McLean PH. Single dose, double-blind, placebo-controlled parallel group study to assess the pharmacokinetics and penetration of ofloxacin otic solution through a tympanostomy tube in adults with suppurative otitis media with otorrhoea. Daiichi Pharmaceutical Corporation, 1995, 1996 Study report protocol 8280-A-PRT 005. (Data on file)
10.
Zurück zum Zitat National Committee for Clinical laboratory Standards. Performance standards for antimicrobial susceptibility testing. 1993, Vol. 17. Villanova (PA): NCCLS, M100-S7 National Committee for Clinical laboratory Standards. Performance standards for antimicrobial susceptibility testing. 1993, Vol. 17. Villanova (PA): NCCLS, M100-S7
11.
Zurück zum Zitat Thomson KS, Sanders CC. The effects of increasing levels of quinolone resistance on in-vitro activity of four quinolones. J Antimicrob Chemother 1998 Aug; 42(2): 179–87PubMedCrossRef Thomson KS, Sanders CC. The effects of increasing levels of quinolone resistance on in-vitro activity of four quinolones. J Antimicrob Chemother 1998 Aug; 42(2): 179–87PubMedCrossRef
12.
Zurück zum Zitat Raza SA, Denholm SW, Wong JC. An audit of the management of acute otitis externa in an ENT casualty clinic. J Laryngol Otol 1995; 109: 130–3PubMedCrossRef Raza SA, Denholm SW, Wong JC. An audit of the management of acute otitis externa in an ENT casualty clinic. J Laryngol Otol 1995; 109: 130–3PubMedCrossRef
13.
Zurück zum Zitat Ruben RJ. Efficacy of ofloxacin and other otic preparations for otitis externa. Pediatr Infect Dis J 2001 Jan; 20(1): 108–10, 120-2PubMedCrossRef Ruben RJ. Efficacy of ofloxacin and other otic preparations for otitis externa. Pediatr Infect Dis J 2001 Jan; 20(1): 108–10, 120-2PubMedCrossRef
14.
Zurück zum Zitat Bluestone CD. Epidemiology and pathogenesis of chronic suppurative otitis media: implications for prevention and treatment. Int J Pediatr Otol 1998; 42: 207–23CrossRef Bluestone CD. Epidemiology and pathogenesis of chronic suppurative otitis media: implications for prevention and treatment. Int J Pediatr Otol 1998; 42: 207–23CrossRef
15.
Zurück zum Zitat Godinho RN, Goncalves TM, Nunes FB, et al. Prevalence and impact of chronic otitis media in school age children in Brazil. First epidemiologic study concerning chronic otitis media in Latin America. Int J Pediatr Otorhinolaryngol 2001 Dec 1; 61(3): 223–32PubMedCrossRef Godinho RN, Goncalves TM, Nunes FB, et al. Prevalence and impact of chronic otitis media in school age children in Brazil. First epidemiologic study concerning chronic otitis media in Latin America. Int J Pediatr Otorhinolaryngol 2001 Dec 1; 61(3): 223–32PubMedCrossRef
16.
Zurück zum Zitat Balle VH, Tos M, Dang HS, et al. Prevalence of chronic otitis media in a randomly selected population from two communes in southern Vietnam. Acta Otolaryngol Suppl 2000; 543: 51–3PubMed Balle VH, Tos M, Dang HS, et al. Prevalence of chronic otitis media in a randomly selected population from two communes in southern Vietnam. Acta Otolaryngol Suppl 2000; 543: 51–3PubMed
17.
Zurück zum Zitat Daly KA, Giebink GS. Clinical epidemiology of otitis media. Pediatr Infect Dis J 2000; 19(5 Suppl.): S31–6PubMed Daly KA, Giebink GS. Clinical epidemiology of otitis media. Pediatr Infect Dis J 2000; 19(5 Suppl.): S31–6PubMed
18.
19.
Zurück zum Zitat Department of Health (UK). Hospital Episode Statistics 2002 Dec; 2000/01 Department of Health (UK). Hospital Episode Statistics 2002 Dec; 2000/01
20.
Zurück zum Zitat Debruyne F, Jorissen M, Poelmans J. Otorrhea during transtympanal ventilation. Am J Otol 1988 Jul; 9(4): 316–7PubMed Debruyne F, Jorissen M, Poelmans J. Otorrhea during transtympanal ventilation. Am J Otol 1988 Jul; 9(4): 316–7PubMed
21.
22.
Zurück zum Zitat Jung T, Rhee CK. Otolaryngologic approach to the diagnosis and management of otitis media. Otolaryngologic Clin North Am 1991; 24: 931–45 Jung T, Rhee CK. Otolaryngologic approach to the diagnosis and management of otitis media. Otolaryngologic Clin North Am 1991; 24: 931–45
23.
Zurück zum Zitat Cantor RM. Otitis externa and otitis media: a new look at old problems. Emerg Med Clin North Am 1995; 13(2): 445–55PubMed Cantor RM. Otitis externa and otitis media: a new look at old problems. Emerg Med Clin North Am 1995; 13(2): 445–55PubMed
24.
Zurück zum Zitat Kempthorne J, Giebink G. Pediatric approach to the diagnosis and management of otitis media. Otolaryngologic Clin North Am 1991; 24: 905–29 Kempthorne J, Giebink G. Pediatric approach to the diagnosis and management of otitis media. Otolaryngologic Clin North Am 1991; 24: 905–29
25.
Zurück zum Zitat Jones RN, Milazzo J, Seidlin M. Ofloxacin otic solution for treatment of otitis externa in children and adults. Arch Otolaryngol Head Neck Surg 1997; 123(11): 1193–200PubMedCrossRef Jones RN, Milazzo J, Seidlin M. Ofloxacin otic solution for treatment of otitis externa in children and adults. Arch Otolaryngol Head Neck Surg 1997; 123(11): 1193–200PubMedCrossRef
26.
Zurück zum Zitat Wintermeyer S, Nahata M. Chonic suppurative otits media. Ann Pharmacol 1994; 28: 1089–99 Wintermeyer S, Nahata M. Chonic suppurative otits media. Ann Pharmacol 1994; 28: 1089–99
27.
Zurück zum Zitat Agro AS, Garner ET, Wright JW, et al. Clinical trial of ototopical ofloxacin for treatment of chronic suppurative otitis media. Clin Ther 1998; 20(4): 744–59PubMedCrossRef Agro AS, Garner ET, Wright JW, et al. Clinical trial of ototopical ofloxacin for treatment of chronic suppurative otitis media. Clin Ther 1998; 20(4): 744–59PubMedCrossRef
28.
Zurück zum Zitat Acuin J, Smith A, Mackenzie I. Interventions for chronic suppurative otitis media. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 2. Oxford: Update Sotware, 2002 Acuin J, Smith A, Mackenzie I. Interventions for chronic suppurative otitis media. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 2. Oxford: Update Sotware, 2002
29.
Zurück zum Zitat Esposito S, Noviello S, D’Errico G, et al. Topical ciprofloxacin versus intramuscular gentamicin for chronic otitis media. Arch Otolaryngol Head Neck Surg 1992; 118: 842–4PubMedCrossRef Esposito S, Noviello S, D’Errico G, et al. Topical ciprofloxacin versus intramuscular gentamicin for chronic otitis media. Arch Otolaryngol Head Neck Surg 1992; 118: 842–4PubMedCrossRef
30.
Zurück zum Zitat Yuen P, Lau S, Chau P, et al. Ofloxacin eardrop treatment for active chronic suppurative otitis media: prospective randomized study. Am J Otol 1994; 15: 670–3PubMed Yuen P, Lau S, Chau P, et al. Ofloxacin eardrop treatment for active chronic suppurative otitis media: prospective randomized study. Am J Otol 1994; 15: 670–3PubMed
31.
Zurück zum Zitat Llorente J, Sabater F, Maristany M, et al. Estudio multicentrico comparativo de la eficacia y tolerancia de ciprofloxacino topico (0.3%) versus gentamicina topica (0.3%) en el tratamiento de la otitis media cronica simple no colesteato-matosa en fase supurativa [Multicenter comparative study of the effectiveness and tolerance of topical ciprofloxacine (0.3%) versus topical gentamicine (0.3%) in the treatment of chronic suppurative otitis media without cholesteatoma]. An Otorrinolaringol Ibero Am 1995; 5: 521–33 Llorente J, Sabater F, Maristany M, et al. Estudio multicentrico comparativo de la eficacia y tolerancia de ciprofloxacino topico (0.3%) versus gentamicina topica (0.3%) en el tratamiento de la otitis media cronica simple no colesteato-matosa en fase supurativa [Multicenter comparative study of the effectiveness and tolerance of topical ciprofloxacine (0.3%) versus topical gentamicine (0.3%) in the treatment of chronic suppurative otitis media without cholesteatoma]. An Otorrinolaringol Ibero Am 1995; 5: 521–33
32.
Zurück zum Zitat Tutkun A, Ozagar A, Koc A, et al. Treatment of chronic ear disease: topical ciprofloxacin vs topical gentamicin. Arch Otolaryngol Head Neck Surg 1995; 121: 1414–6PubMedCrossRef Tutkun A, Ozagar A, Koc A, et al. Treatment of chronic ear disease: topical ciprofloxacin vs topical gentamicin. Arch Otolaryngol Head Neck Surg 1995; 121: 1414–6PubMedCrossRef
33.
Zurück zum Zitat Tong MC, Woo JK, van Hasselt CA. A double blind comparative study of ofloxacin otic drops versus neomycin-polymyxin B-hydrocortisone otic drops in the medical treatment of chronic suppurative otitis media. J Laryngol Otol 1996; 110(4): 309–14PubMedCrossRef Tong MC, Woo JK, van Hasselt CA. A double blind comparative study of ofloxacin otic drops versus neomycin-polymyxin B-hydrocortisone otic drops in the medical treatment of chronic suppurative otitis media. J Laryngol Otol 1996; 110(4): 309–14PubMedCrossRef
34.
Zurück zum Zitat Abes G, Espallardo N, Tong M, et al. A systematic review of the effectiveness of ofloxacin otic solution for the treatment of suppurative otitis media. Internal report Daiichi Pharmaceutical Corporation, Feb 2001 Abes G, Espallardo N, Tong M, et al. A systematic review of the effectiveness of ofloxacin otic solution for the treatment of suppurative otitis media. Internal report Daiichi Pharmaceutical Corporation, Feb 2001
35.
Zurück zum Zitat Boesoirie T. A comparative study between ofloxacin ear drops and neomycin-polymixin b-hydrocortisone ear drops on the chronic suppurative otitis media. Presented at the 9th ASEAN ORL Head & Neck Congress; 2001 Mar 31-Apr 1, Singapore Boesoirie T. A comparative study between ofloxacin ear drops and neomycin-polymixin b-hydrocortisone ear drops on the chronic suppurative otitis media. Presented at the 9th ASEAN ORL Head & Neck Congress; 2001 Mar 31-Apr 1, Singapore
36.
Zurück zum Zitat Helmi A, Ratna D, Zainul A, et al. The efficacy and safety of ofloxacin otic solution for active suppurative otitis media. Presented at the 9th ASEAN ORL Head & Neck Congress; 2001 Mar 31-Apr 1, Singapore Helmi A, Ratna D, Zainul A, et al. The efficacy and safety of ofloxacin otic solution for active suppurative otitis media. Presented at the 9th ASEAN ORL Head & Neck Congress; 2001 Mar 31-Apr 1, Singapore
37.
Zurück zum Zitat Subramaniam K, Jalaludin M, Krishnan G. Comparative study of ofloxacin otic drops versus neomycin-polymixin b-hydrocortisone in the medical management of chronic suppurative otitis media. Presented at the 9th ASEAN ORL Head & Neck Congress; 2001 Mar 31-Apr 1, Singapore Subramaniam K, Jalaludin M, Krishnan G. Comparative study of ofloxacin otic drops versus neomycin-polymixin b-hydrocortisone in the medical management of chronic suppurative otitis media. Presented at the 9th ASEAN ORL Head & Neck Congress; 2001 Mar 31-Apr 1, Singapore
38.
Zurück zum Zitat Abes J, Jamir J, Gloria-Cruz MT, et al. Comparative efficacy and safety of ofloxacin and polymixin otic drops for chronic suppurative otitis media. UPMJ 1998; 4(1): 59–70 Abes J, Jamir J, Gloria-Cruz MT, et al. Comparative efficacy and safety of ofloxacin and polymixin otic drops for chronic suppurative otitis media. UPMJ 1998; 4(1): 59–70
39.
Zurück zum Zitat Supiyaphun P, Chochaipanichnon L, Tonsakulrungruang K, et al. The treatment of chronic suppurative otitis media and otitis externa with 0.3 per cent ofloxacin otic solution: a clinicomicrobiologic study. J Med Assoc Thail 1995; 78(1): 18–21 Supiyaphun P, Chochaipanichnon L, Tonsakulrungruang K, et al. The treatment of chronic suppurative otitis media and otitis externa with 0.3 per cent ofloxacin otic solution: a clinicomicrobiologic study. J Med Assoc Thail 1995; 78(1): 18–21
40.
Zurück zum Zitat Gendeh S. A comparative study of ofloxacin otic drops vs framycetin sulfate-dexamethasone-gramicidin otic drops in the medical treatment of otitis externa and chronic suppurative otitis media. Presented at the 9th ASEAN ORL Head & Neck Congress; 2001 Mar 31-Apr 1, Singapore Gendeh S. A comparative study of ofloxacin otic drops vs framycetin sulfate-dexamethasone-gramicidin otic drops in the medical treatment of otitis externa and chronic suppurative otitis media. Presented at the 9th ASEAN ORL Head & Neck Congress; 2001 Mar 31-Apr 1, Singapore
41.
Zurück zum Zitat Dohar J, Garner E, Nielsen R, et al. Topical ofloxacin treatment of otorrhea in children with tympanostomy tubes. Arch Otol Head Neck Surg 1999; 125(5): 537–45 Dohar J, Garner E, Nielsen R, et al. Topical ofloxacin treatment of otorrhea in children with tympanostomy tubes. Arch Otol Head Neck Surg 1999; 125(5): 537–45
42.
Zurück zum Zitat Tong MC, Yue V, Ku PK, et al. Preoperative topical ofloxacin solution for tympanoplasty: a randomized, controlled study. Otol Neurotol 2002 Jan; 23(1): 18–20PubMedCrossRef Tong MC, Yue V, Ku PK, et al. Preoperative topical ofloxacin solution for tympanoplasty: a randomized, controlled study. Otol Neurotol 2002 Jan; 23(1): 18–20PubMedCrossRef
43.
Zurück zum Zitat Gates GA, Avery C, Prihoda TJ, et al. Delayed onset post-tympanotomy otorrhea. Otolaryngol Head Neck Surg 1988 Feb; 98(2): 111–5PubMed Gates GA, Avery C, Prihoda TJ, et al. Delayed onset post-tympanotomy otorrhea. Otolaryngol Head Neck Surg 1988 Feb; 98(2): 111–5PubMed
44.
Zurück zum Zitat Goldblatt EL. Efficacy of ofloxacin and other otic preparations for acute otitis media in patients with tympanostomy tubes. Pediatr Infect Dis J 2001; 20(1): 116–9PubMedCrossRef Goldblatt EL. Efficacy of ofloxacin and other otic preparations for acute otitis media in patients with tympanostomy tubes. Pediatr Infect Dis J 2001; 20(1): 116–9PubMedCrossRef
45.
Zurück zum Zitat Hawkins JE. Drug ototoxicity in Handbook of sensory physiology. Vol 5. Berlin: Springer-Verlag, 1976: 707–48 Hawkins JE. Drug ototoxicity in Handbook of sensory physiology. Vol 5. Berlin: Springer-Verlag, 1976: 707–48
46.
Zurück zum Zitat Dreschler WA, van de Hulst RJ, Tange RA, et al. The role of high-frequency audiometry in early detection of ototoxicity. Audiology 1985; 24(6): 387–95PubMedCrossRef Dreschler WA, van de Hulst RJ, Tange RA, et al. The role of high-frequency audiometry in early detection of ototoxicity. Audiology 1985; 24(6): 387–95PubMedCrossRef
47.
Zurück zum Zitat Lundy LB, Graham MD. Ototoxicity and ototopical medications: a survey of otolaryngologists. Am J Otol 1993; 14(2): 141–6PubMed Lundy LB, Graham MD. Ototoxicity and ototopical medications: a survey of otolaryngologists. Am J Otol 1993; 14(2): 141–6PubMed
48.
Zurück zum Zitat Linder TE, Zwicky S, Brandle P. Ototoxicity of ear drops: a clinical perspective. Am J Otol 1995; 16(5): 653–7PubMed Linder TE, Zwicky S, Brandle P. Ototoxicity of ear drops: a clinical perspective. Am J Otol 1995; 16(5): 653–7PubMed
49.
Zurück zum Zitat Welling DB, Forrest LA, Goll III F. Safety of ototopical antibiotics. Laryngoscope 1995; 105(5 Pt 1): 472–4PubMedCrossRef Welling DB, Forrest LA, Goll III F. Safety of ototopical antibiotics. Laryngoscope 1995; 105(5 Pt 1): 472–4PubMedCrossRef
50.
Zurück zum Zitat Wong DL, Rutka JA. Do aminoglycoside otic preparations cause ototoxicity in the presence of tympanic membrane perforations? Otolaryngol Head Neck Surg 1997; 116(3): 404–10PubMedCrossRef Wong DL, Rutka JA. Do aminoglycoside otic preparations cause ototoxicity in the presence of tympanic membrane perforations? Otolaryngol Head Neck Surg 1997; 116(3): 404–10PubMedCrossRef
51.
Zurück zum Zitat Russell PT, Church CA, Jinn TH, et al. Effects of common topical otic preparations on the morphology of isolated cochlear outer hair cells. Acta Otolaryngolog 2001; 121(2): 135–9CrossRef Russell PT, Church CA, Jinn TH, et al. Effects of common topical otic preparations on the morphology of isolated cochlear outer hair cells. Acta Otolaryngolog 2001; 121(2): 135–9CrossRef
52.
Zurück zum Zitat Barlow DW, Duckert LG, Kreig CS, et al. Ototoxicity of topical otomicrobial agents. Acta Otolaryngol 1995 Mar; 115(2): 231–5PubMedCrossRef Barlow DW, Duckert LG, Kreig CS, et al. Ototoxicity of topical otomicrobial agents. Acta Otolaryngol 1995 Mar; 115(2): 231–5PubMedCrossRef
53.
Zurück zum Zitat Halama AR, Wright CG, Meyerhoff WL. Ototoxicity of an ototopic preparation: experimental results and clinical facts. Acta Otorhinolaryngol Belg 1991; 45(3): 279–82PubMed Halama AR, Wright CG, Meyerhoff WL. Ototoxicity of an ototopic preparation: experimental results and clinical facts. Acta Otorhinolaryngol Belg 1991; 45(3): 279–82PubMed
54.
Zurück zum Zitat Podoshin L, Fradis M, Ben David J. Ototoxicity of ear drops in patients suffering from chronic otitis media. J Laryngol Otol 1989 Jan; 103(1): 46–50PubMedCrossRef Podoshin L, Fradis M, Ben David J. Ototoxicity of ear drops in patients suffering from chronic otitis media. J Laryngol Otol 1989 Jan; 103(1): 46–50PubMedCrossRef
55.
Zurück zum Zitat Bureau of Drug Surveillance health, Canada. The Canadian Adverse Drug Reaction Newsletter 1997 Apr; 7 (2) Bureau of Drug Surveillance health, Canada. The Canadian Adverse Drug Reaction Newsletter 1997 Apr; 7 (2)
56.
Zurück zum Zitat Christ W, Lehnert T, Ulbrich B. Specific toxicologic aspects of the quinolones. Rev Infect Dis 1988; 10Suppl. 1: S141–6PubMedCrossRef Christ W, Lehnert T, Ulbrich B. Specific toxicologic aspects of the quinolones. Rev Infect Dis 1988; 10Suppl. 1: S141–6PubMedCrossRef
57.
Zurück zum Zitat Kato M, Akahane K, Shimoda K. Lack of chondrotoxicity of ofloxacin otic solution on the auditory ossicle cartilages of juvenile guinea pigs. J Antimicrob Chemother 1997; 39(2): 269–71PubMedCrossRef Kato M, Akahane K, Shimoda K. Lack of chondrotoxicity of ofloxacin otic solution on the auditory ossicle cartilages of juvenile guinea pigs. J Antimicrob Chemother 1997; 39(2): 269–71PubMedCrossRef
58.
Zurück zum Zitat Daiichi Pharmaceutical Corporation, 2002. (Data on file.) Daiichi Pharmaceutical Corporation, 2002. (Data on file.)
59.
Zurück zum Zitat Daiichi Pharmaceutical Corporation, 2002. (Data on file.) Daiichi Pharmaceutical Corporation, 2002. (Data on file.)
60.
Zurück zum Zitat Black HE, Schaefer GJ, Dolan DF, et al. Preclinical study of the ototoxic potential of an otic solution of ofloxacin. Abstract and Poster presented at the 12th Annual Meeting of the American Society of Pediatric Otolaryngology; 1997 May 14-16; Scottsdale (AZ) Black HE, Schaefer GJ, Dolan DF, et al. Preclinical study of the ototoxic potential of an otic solution of ofloxacin. Abstract and Poster presented at the 12th Annual Meeting of the American Society of Pediatric Otolaryngology; 1997 May 14-16; Scottsdale (AZ)
61.
Zurück zum Zitat Gates GA. Safety of ofloxacin otic and other ototopical treatments in animal models and in humans. Pediatr Infect Dis J 2001; 20(1): 104–7; 120-2PubMedCrossRef Gates GA. Safety of ofloxacin otic and other ototopical treatments in animal models and in humans. Pediatr Infect Dis J 2001; 20(1): 104–7; 120-2PubMedCrossRef
Metadaten
Titel
A Benefit-Risk Assessment of Ofloxacin Otic Solution in Ear Infection
verfasst von
Talen K.H. Wai
Dr Michael C.F. Tong
Publikationsdatum
01.05.2003
Verlag
Springer International Publishing
Erschienen in
Drug Safety / Ausgabe 6/2003
Print ISSN: 0114-5916
Elektronische ISSN: 1179-1942
DOI
https://doi.org/10.2165/00002018-200326060-00003

Weitere Artikel der Ausgabe 6/2003

Drug Safety 6/2003 Zur Ausgabe